Pfizer Diflucan giveaway
$1.6 mil worth of new antifungal fluconazole will be distributed to 200 major AIDS and cancer treatment centers "to ensure that patients in critical need will receive it immediately," Pfizer said. Approved Jan. 29 for AIDS-related infections ("The Pink Sheet" Feb. 5, p. 5), Pfizer is touting the drug's cost effectiveness, citing a retrospective European study that found patients on Diflucan were hospitalized for an average of 14.3 days compared to 31.6 days for patients on amphotericin B. Price to wholesalers for the drug, announced Feb. 7, is $9 per 200 mg, $270 per bottle of 30 tabs.
You may also be interested in...
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.
Developing biosimilar orphan drugs is fraught with challenges and needs buy-in from regulators, developers, patients and clinicians.